Trial Profile
Prospective study of effect of Bortezomib on PFS in multiple myeloma patients overexpressing the preferentially expressed antigen of melanoma (PRAME)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Nov 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Epirubicin; Thalidomide; Vindesine
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Nov 2015 New trial record